RKDA|EPS -$0.97|Rev $901,000|Net Loss $1.4MArcadia Biosciences produces innovative wellness products. Recently, the company terminated a proposed business combination with Roosevelt Resources. Arcadia is now focused on growing its Zola® coconut water brand while evaluating strategic alternatives.
For the full year 2025, total revenues were $4,858,000. The net loss (EPS) was $1.71 per share for the year. Fourth-quarter revenues were $901,000 , with an EPS loss of $0.97 per share.
Zola brand revenues increased 17% year-over-year. Furthermore, Arcadia secured approximately $2.1 million in gross proceeds from the exercise of preferred investment options to improve its balance sheet.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.
The post Arcadia Biosciences 2025 Financial Results first appeared on Alphastreet.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
